Ireland-based molecular diagnostics company HiberGene Diagnostics today announced that they have expedited the design of a new, rapid near-patient molecular test for Novel Coronavirus 2019-nCoV.
The test uses the company’s proprietary reagent format and low-complexity sample protocol to quickly detect the virus in clinical samples. It allows delivery of results within 60 minutes, without the need for segregated laboratory facilities or highly trained staff.
Simona Esposito, Chief Executive Officer of HiberGene, said: “Our research and development team have reacted quickly to the outbreak of Coronavirus. Using the template of our CE-marked Flu and RSV respiratory tests we have been able to develop a specific and sensitive Coronavirus assay which utilises our easy-to-use, freeze-dried reagent format to facilitate near-patient testing.”
The new test is set to undergo clinical evaluation in China in collaboration with HiberGene’s distribution partner in Shenzhen, Medcaptain Medical Technologies.
“Our ongoing Chinese clinical trials of HiberGene’s Group B Streptococcus test have delivered excellent results to date. We look forward to similar performance from their new Coronavirus test, which has the potential to make significant impact on patient outcomes and infection control,” said Justin Liu, CEO of Medcaptain.
Community pharmacy is key to a primary care of the future that focuses on prevention
Santosh Sahu